China’s Alzheimer’s Drug Derailed as Global Trial Terminated
- Green Valley ends study after Covid disruptions, funding woes
- Company aims to attempt another trial when conditions improve
This article is for subscribers only.
A global clinical trial of a drug that has been approved in China for treating Alzheimer’s disease was terminated because of a lack of funding and Covid-19 disruptions, the developer said.
Covid’s resurgence across several regions made completing the study of oligomannate, also known as GV-971, hard because many patients couldn’t show up for follow-up visits, according to Green Valley Pharmaceutical Co. Demand for the company’s drugs has been sluggish during the pandemic, and it also failed to secure external funding, which made investing more in the trial difficult.